Last reviewed · How we verify

NCT03523741

Therapeutic Drug Monitoring for Individualized Clozapine Therapy

Status unknown Last updated 24 September 2019
What this trial tests

trial testing Clozapine in Schizophrenia in 100 participants. Status unknown.

Timeline
13 June 2018
Primary endpoint
30 November 2020
31 December 2020

Quick facts

Lead sponsorSeoul National University Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment100
Start date13 June 2018
Primary completion30 November 2020
Estimated completion31 December 2020
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Seoul National University Hospital

Who can join

19 and older, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the factors affecting the occurrence of adverse drug reactions (glucose and lipid metabolism abnormality, changes in liver function index and sleeping tendency) and clinical effects in schizophrenia patients with clozapine treatment

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Clozapine

Trials testing the same drug.

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

Other Seoul National University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03523741.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing